Evidence map›Paper›PMID 29989651›Full record

ArticleOncology reports2018

Osthole enhances antitumor activity and irradiation sensitivity of cervical cancer cells by suppressing ATM/NF‑κB signaling.

Yilin Che, Juan Li, Zongjuan Li, Jing Li, Shuai Wang, Ying Yan, Kun Zou, Lijuan Zou

Open access · hybridAbstract read
In one paragraph

Article in Oncology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Exploring Natural Coumarins: Breakthroughs in Anticancer Therapeutics.Anti-cancer agents in medicinal chemistry · 2026
    Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Copper in Gynecological Diseases.International journal of molecular sciences · 2023
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Yilin CheDepartment of Radiotherapy Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116027, P.R. China.
Juan LiDepartment of Radiotherapy Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116027, P.R. China.
Zongjuan LiDepartment of Radiotherapy Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116027, P.R. China.
Jing LiDepartment of Cardiology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, P.R. China.
Shuai WangDepartment of Ophthalmology, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116027, P.R. China.
Ying YanDepartment of Radiotherapy Oncology, The General Hospital of Shenyang Military Command, Shenyang, Liaoning 110016, P.R. China.
Kun ZouDepartment of Radiotherapy Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, P.R. China.
Lijuan ZouDepartment of Radiotherapy Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116027, P.R. China.
Dalian Medical University · CNFirst Affiliated Hospital of Dalian Medical University · CNGeneral Hospital of Shenyang Military Region · CNSecond Affiliated Hospital of Dalian Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osthole (7‑methoxy‑8‑isopentenoxycoumarin) is an O‑methylated coumarin, originally extracted from Chinese herbal medicine. It has been demonstrated that osthole has antitumor effects in various cancer cells in vitro. The present study assessed the effects of osthole on the regulation of cervical cancer cell viability, apoptosis, and radiation sensitization. HeLa, SiHa, C‑33A and CaSki cervical cancer cell lines were cultured and treated with osthole and/or irradiation and then subjected to 3‑(4,5‑dimethylthiazol‑2‑yl)‑2,5‑-diphenyl‑tetrazolium bromide cell viability, colony formation, apoptosis, acridine orange/ethidium bromide fluorescence staining, wound‑healing, Transwell migration and invasion, immunofluorescence, Comet and western blot assays. The data showed that osthole dose‑dependently reduced cervical cancer cell viability, proliferation, and migration and invasion, but induced apoptosis. At the protein level, osthole affected the expression of cervical cancer cell epithelial‑mesenchymal transition markers, which showed that the expression of E‑cadherin was increased, whereas that of vimentin was decreased. Osthole treatment also sensitized cervical cancer cells to irradiation, showing increased DNA damage as assessed by the Comet assay, and inhibited nuclear factor‑κB signaling. In conclusion, osthole is an herbal agent that may offer potential for used as an adjuvant treatment for cervical cancer.

Indexed as

ApoptosisAtaxia Telangiectasia Mutated ProteinsCell Line, TumorCell SurvivalChemoradiotherapyCnidiumCoumarinsDose-Response Relationship, DrugDrugs, Chinese HerbalEpithelial-Mesenchymal TransitionFemaleHumansNF-kappa BRadiation ToleranceSignal TransductionUterine Cervical NeoplasmsAtaxia Telangiectasia Mutated ProteinsATM protein, humanCoumarinsDrugs, Chinese HerbalNF-kappa Bosthol

Identifiers

PMID29989651
PMCPMC6072300
OpenAlexW2809589307

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.